- Trade Name: Tudorza Pressair (Forest)
- Indications: Long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema
- Class: Anticholinergic, Muscarinic antagonist
- Half-life: 5–8 hours
- FDA Approval Date: 07/30/2012
- Clinically important, potentially hazardous interactions with:
Anticholinergics
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
